Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TK-03 injectable emulsion in acute ischemic stroke
CTR20254832Phase 2Active
- Sponsor
- Xinrui Taikang
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alpha-asarone in ischemic stroke (4 arms), sponsored by Xinrui Taikang. Primary endpoint: Change from baseline in NIHSS score at Day 10. Started Mar 2026; status: active.
02
Drugs
alpha-asarone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20254832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254832.